サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442901

無菌注射薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

Sterile Injectable Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 222 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
無菌注射薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年
出版日: 2024年01月03日
発行: Transparency Market Research
ページ情報: 英文 222 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

無菌注射薬市場 - レポートの範囲

アルツハイマー病に関連する世界の認知症市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の認知症市場の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間のアルツハイマー病市場に関連付けられています。レポートは、2023年から2031年までの世界のアルツハイマー病に関連する認知症市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、アルツハイマー病市場に関連する認知症を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、アルツハイマー病に関連する世界の認知症市場の競合情勢を詳しく掘り下げています。アルツハイマー病に関連する世界の認知症市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで概説されているアルツハイマー病に関連する世界の認知症市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • パイプライン分析
  • キーの種類/ブランド分析
  • 主な合併と買収
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：タイプ別、2017年～2031年
    • 低分子
    • 高分子
  • 市場の魅力：タイプ別

第7章 世界市場の分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤クラス別、2017年～2031年
    • モノクローナル抗体（Mab）
    • サイトカイン
    • インスリン
    • ペプチドホルモン
    • ワクチン
    • 免疫グロブリン
    • 血液因子
    • ペプチド抗生物質
    • その他
  • 市場の魅力度：薬剤クラス別

第8章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：適応症別、2017年～2031年
    • 心臓病と代謝疾患
    • 神経内科
    • 腫瘍学
    • 自己免疫
    • 消化器科
    • 血液学
    • 痛み
    • 感染症
    • その他
  • 市場の魅力：適応症別

第9章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2017年～2031年
    • 病院薬局
    • 小売薬局
    • eコマース
  • 市場の魅力：流通チャネル別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東・アフリカ市場; 分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場金額予測：タイプ別、2017年～2031年
    • 低分子
    • 高分子
  • 市場の魅力：タイプ別
  • 市場金額予測：薬剤クラス別、2017年～2031年
    • モノクローナル抗体（Mab）
    • サイトカイン
    • インスリン
    • ペプチドホルモン
    • ワクチン
    • 免疫グロブリン
    • 血液因子
    • ペプチド抗生物質
    • その他
  • 市場の魅力度：薬剤クラス別
  • 市場金額予測：指標別、2017年～2031年
    • 心臓病と代謝疾患
    • 神経内科
    • 腫瘍学
    • 自己免疫
    • 消化器科
    • 血液学
    • 痛み
    • 感染症
    • その他
  • 市場の魅力：適応症別
  • 市場金額予測：流通チャネル別、2017年～2031年
    • 病院薬局
    • 小売薬局
    • eコマース
  • 市場の魅力：流通チャネル別
  • 市場金額予測：国/サブ地域別、2017年～2031年
    • GCC諸国
    • 南アフリカ
    • その他中東・アフリカ
  • 市場の魅力分析
    • タイプ別
    • 薬剤クラス別
    • 適応症別
    • 流通チャネル別
    • 国/サブ地域別

第16章 競合情勢

  • 市場企業-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Baxter International
    • Sanofi SA
    • Pfizer, Inc.
    • GlaxoSmithKline Plc.
    • AstraZeneca
    • Merck &Co., Inc.
    • Novartis AG
    • Johnson &Johnson Services, Inc.
    • Novo Nordisk A/S
    • Gilead Sciences, Inc.
図表

List of Tables

  • Table 01: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 03: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 05: Global Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 09: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 10: North America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 11: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 14: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Europe Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Asia Pacific Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 25: Latin America Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 26: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 29: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 30: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Sterile Injectable Drugs Market Size (US$ Mn), by Region, 2022 and 2031
  • Figure 02: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Type, 2022
  • Figure 03: Global Sterile Injectable Drugs Market Value Share, by Type, 2022
  • Figure 04: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Drug Class, 2022
  • Figure 05: Global Sterile Injectable Drugs Market Value Share, by Drug Class, 2022
  • Figure 06: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Indication, 2022
  • Figure 07: Global Sterile Injectable Drugs Market Value Share, by Indication, 2022
  • Figure 08: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 09: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 10: Global Sterile Injectable Drugs Market Value Share, by Region, 2022
  • Figure 11: Global Sterile Injectable Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 12: Global Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 13: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 14: Global Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 15: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 16: Global Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 17: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 18: Global Sterile Injectable Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 19: Global Sterile Injectable Drugs Market Value Share, by Distribution Channel, 2022
  • Figure 20: Global Sterile Injectable Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 21: Global Sterile Injectable Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 22: North America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 23: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 24: North America Sterile Injectable Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 25: North America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 26: North America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 27: North America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 28: North America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 29: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 30: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 31: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 32: North America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 33: Europe Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 34: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 35: Europe Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 36: Europe Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 37: Europe Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 38: Europe Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 39: Europe Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 41: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 42: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 43: Europe Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 44: Asia Pacific Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 45: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 46: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 47: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 48: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 49: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 50: Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 52: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 53: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 54: Asia Pacific Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 55: Latin America Sterile Injectable Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 56: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 57: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 58: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 59: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 60: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 61: Latin America Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 62: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 63: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 64: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 65: Latin America Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 66: Middle East & Africa Sterile Injectable Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 67: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 68: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 69: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Type, 2022 and 2031
  • Figure 70: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 71: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 72: Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 73: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 74: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 75: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 76: Middle East & Africa Sterile Injectable Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
目次
Product Code: TMRGL34427

Sterile Injectable Drugs Market - Scope of Report

TMR's report on the global dementia associated with Alzheimer's disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer's disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer's disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer's disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer's disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer's disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer's disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer's disease market. Key players operating in the global dementia associated with Alzheimer's disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer's disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer's disease Market Report:

  • What is the sales/revenue generated by dementia associated with Alzheimer's disease across all regions during the forecast period?
  • What are the opportunities in the global dementia associated with Alzheimer's disease market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Sterile Injectable Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer's disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer's disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer's disease market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sterile Injectable Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Sterile Injectable Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Type/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Sterile Injectable Drugs Market Analysis and Forecast, by Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Small Molecule
    • 6.3.2. Large Molecule
  • 6.4. Market Attractiveness, by Type

7. Global Sterile Injectable Drugs Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Drug Class, 2017-2031
    • 7.3.1. Monoclonal Antibodies (Mabs)
    • 7.3.2. Cytokines
    • 7.3.3. Insulin
    • 7.3.4. Peptide Hormones
    • 7.3.5. Vaccine
    • 7.3.6. Immunoglobulins
    • 7.3.7. Blood Factors
    • 7.3.8. Peptide Antibiotics
    • 7.3.9. Others
  • 7.4. Market Attractiveness, by Drug Class

8. Global Sterile Injectable Drugs Market Analysis and Forecast, by Indication

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Cardiology & Metabolic Disorders
    • 8.3.2. Neurology
    • 8.3.3. Oncology
    • 8.3.4. Autoimmune
    • 8.3.5. Gastroenterology
    • 8.3.6. Hematology
    • 8.3.7. Pain
    • 8.3.8. Infectious Disease
    • 8.3.9. Others
  • 8.4. Market Attractiveness, by Indication

9. Global Sterile Injectable Drugs Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. E-commerce
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Sterile Injectable Drugs Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Sterile Injectable Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Small Molecule
    • 11.2.2. Large Molecule
  • 11.3. Market Attractiveness, by Type
  • 11.4. Market Value Forecast, by Drug Class, 2017-2031
    • 11.4.1. Monoclonal Antibodies (Mabs)
    • 11.4.2. Cytokines
    • 11.4.3. Insulin
    • 11.4.4. Peptide Hormones
    • 11.4.5. Vaccine
    • 11.4.6. Immunoglobulins
    • 11.4.7. Blood Factors
    • 11.4.8. Peptide Antibiotics
    • 11.4.9. Others
  • 11.5. Market Attractiveness, by Drug Class
  • 11.6. Market Value Forecast, by Indication, 2017-2031
    • 11.6.1. Cardiology & Metabolic Disorders
    • 11.6.2. Neurology
    • 11.6.3. Oncology
    • 11.6.4. Autoimmune
    • 11.6.5. Gastroenterology
    • 11.6.6. Hematology
    • 11.6.7. Pain
    • 11.6.8. Infectious Disease
    • 11.6.9. Others
  • 11.7. Market Attractiveness, by Indication
  • 11.8. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. E-commerce
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Type
    • 11.11.2. By Drug Class
    • 11.11.3. By Indication
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Sterile Injectable Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Small Molecule
    • 12.2.2. Large Molecule
  • 12.3. Market Attractiveness, by Type
  • 12.4. Market Value Forecast, by Drug Class, 2017-2031
    • 12.4.1. Monoclonal Antibodies (Mabs)
    • 12.4.2. Cytokines
    • 12.4.3. Insulin
    • 12.4.4. Peptide Hormones
    • 12.4.5. Vaccine
    • 12.4.6. Immunoglobulins
    • 12.4.7. Blood Factors
    • 12.4.8. Peptide Antibiotics
    • 12.4.9. Others
  • 12.5. Market Attractiveness, by Drug Class
  • 12.6. Market Value Forecast, by Indication, 2017-2031
    • 12.6.1. Cardiology & Metabolic Disorders
    • 12.6.2. Neurology
    • 12.6.3. Oncology
    • 12.6.4. Autoimmune
    • 12.6.5. Gastroenterology
    • 12.6.6. Hematology
    • 12.6.7. Pain
    • 12.6.8. Infectious Disease
    • 12.6.9. Others
  • 12.7. Market Attractiveness, by Indication
  • 12.8. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. E-commerce
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Type
    • 12.11.2. By Drug Class
    • 12.11.3. By Indication
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Sterile Injectable Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Small Molecule
    • 13.2.2. Large Molecule
  • 13.3. Market Attractiveness, by Type
  • 13.4. Market Value Forecast, by Drug Class, 2017-2031
    • 13.4.1. Monoclonal Antibodies (Mabs)
    • 13.4.2. Cytokines
    • 13.4.3. Insulin
    • 13.4.4. Peptide Hormones
    • 13.4.5. Vaccine
    • 13.4.6. Immunoglobulins
    • 13.4.7. Blood Factors
    • 13.4.8. Peptide Antibiotics
    • 13.4.9. Others
  • 13.5. Market Attractiveness, by Drug Class
  • 13.6. Market Value Forecast, by Indication, 2017-2031
    • 13.6.1. Cardiology & Metabolic Disorders
    • 13.6.2. Neurology
    • 13.6.3. Oncology
    • 13.6.4. Autoimmune
    • 13.6.5. Gastroenterology
    • 13.6.6. Hematology
    • 13.6.7. Pain
    • 13.6.8. Infectious Disease
    • 13.6.9. Others
  • 13.7. Market Attractiveness, by Indication
  • 13.8. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. E-commerce
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Type
    • 13.11.2. By Drug Class
    • 13.11.3. By Indication
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Sterile Injectable Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Small Molecule
    • 14.2.2. Large Molecule
  • 14.3. Market Attractiveness, by Type
  • 14.4. Market Value Forecast, by Drug Class, 2017-2031
    • 14.4.1. Monoclonal Antibodies (Mabs)
    • 14.4.2. Cytokines
    • 14.4.3. Insulin
    • 14.4.4. Peptide Hormones
    • 14.4.5. Vaccine
    • 14.4.6. Immunoglobulins
    • 14.4.7. Blood Factors
    • 14.4.8. Peptide Antibiotics
    • 14.4.9. Others
  • 14.5. Market Attractiveness, by Drug Class
  • 14.6. Market Value Forecast, by Indication, 2017-2031
    • 14.6.1. Cardiology & Metabolic Disorders
    • 14.6.2. Neurology
    • 14.6.3. Oncology
    • 14.6.4. Autoimmune
    • 14.6.5. Gastroenterology
    • 14.6.6. Hematology
    • 14.6.7. Pain
    • 14.6.8. Infectious Disease
    • 14.6.9. Others
  • 14.7. Market Attractiveness, by Indication
  • 14.8. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. E-commerce
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Type
    • 14.11.2. By Drug Class
    • 14.11.3. By Indication
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Sterile Injectable Drugs Market ;Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Type, 2017-2031
    • 15.2.1. Small Molecule
    • 15.2.2. Large Molecule
  • 15.3. Market Attractiveness, by Type
  • 15.4. Market Value Forecast, by Drug Class, 2017-2031
    • 15.4.1. Monoclonal Antibodies (Mabs)
    • 15.4.2. Cytokines
    • 15.4.3. Insulin
    • 15.4.4. Peptide Hormones
    • 15.4.5. Vaccine
    • 15.4.6. Immunoglobulins
    • 15.4.7. Blood Factors
    • 15.4.8. Peptide Antibiotics
    • 15.4.9. Others
  • 15.5. Market Attractiveness, by Drug Class
  • 15.6. Market Value Forecast, by Indication, 2017-2031
    • 15.6.1. Cardiology & Metabolic Disorders
    • 15.6.2. Neurology
    • 15.6.3. Oncology
    • 15.6.4. Autoimmune
    • 15.6.5. Gastroenterology
    • 15.6.6. Hematology
    • 15.6.7. Pain
    • 15.6.8. Infectious Disease
    • 15.6.9. Others
  • 15.7. Market Attractiveness, by Indication
  • 15.8. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. E-commerce
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Type
    • 15.11.2. By Drug Class
    • 15.11.3. By Indication
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Baxter International
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Type Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Sanofi S.A
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Type Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Pfizer, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Type Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. GlaxoSmithKline Plc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Type Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. AstraZeneca
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Type Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Type Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Type Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Johnson & Johnson Services, Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Type Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Novo Nordisk A/S
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Type Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Gilead Sciences, Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Type Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview